<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39331">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594371</url>
  </required_header>
  <id_info>
    <org_study_id>KX-ORAX-001</org_study_id>
    <nct_id>NCT02594371</nct_id>
  </id_info>
  <brief_title>Ph3 Study To Determine Safety,Tolerability&amp;Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer</brief_title>
  <official_title>An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinex Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kinex Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and tolerability of Oraxol as compared to IV paclitaxel in
      metastatic breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, open-label, randomized, multicenter study in approximately 360 adult
      female subjects with histologically- or cytologically-confirmed breast cancer that is
      metastatic for whom treatment with IV paclitaxel monotherapy has been recommended by their
      oncologist. Approximately 400 subjects will be enrolled to provide 360 evaluable subjects.
      The subjects must have measurable metastatic target lesion disease as per RECIST v1.1
      criteria. Subjects will be randomized in a 2:1 ratio to either Oraxol or IV paclitaxel (as
      Taxol or generic).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response as determined by response criteria</measure>
    <time_frame>19 to 22 weeks</time_frame>
    <description>Tumor response is evaluated using the response evaluation criteria in solid tumors (RECIST v1.1 criteria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability assessments of Oraxol compared with IV paclitaxel, as determined by laboratory, adverse event (AE) and serious adverse event (SAE) information</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Safety assessments will consist of determining and recording all AEs and SAEs; laboratory evaluation of hematology, blood chemistry, and urine analyses; periodic measurement of vital signs and electrocardiograms (ECGs); and the performance of physical examinations, as detailed in the schedule of procedures and assessments of the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From randomization to end of treatment, up to 48 weeks</time_frame>
    <description>The endpoint of progression-free survival is defined as not having died or progression of disease. Lost to follow-up will be considered as censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to end of treatment, up to 48 weeks</time_frame>
    <description>The endpoint of overall survival is defined as death, confirmed alive, and lost to follow-up. Alive and lost to follow-up will be considered as censored.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Oraxol (paclitaxel + HM30181AK-US)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oraxol paclitaxel - supplied as 30-mg capsules
Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV paclitaxel - supplied as Taxol or generic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oraxol</intervention_name>
    <arm_group_label>Oraxol (paclitaxel + HM30181AK-US)</arm_group_label>
    <other_name>HM30181 methanesulfonate monohydrate</other_name>
    <other_name>Oral paclitaxel capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV paclitaxel</intervention_name>
    <arm_group_label>IV paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Subjects must meet all of the following criteria to be included in this study:

          1. Signed written informed consent

          2. Women ≥18 years of age

          3. Histologically- or cytologically-confirmed breast cancer for whom IV paclitaxel (as
             Taxol or generic) monotherapy has been recommended by their oncologist

          4. Measurable metastatic target lesion disease as per RECIST v1.1 criteria

          5. Adequate hematological status

          6. Adequate liver function

          7. Adequate renal function

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          9. Life expectancy of at least 6 months

         10. Subjects must be postmenopausal (≥12 months without menses) or surgically sterile
             (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective
             contraception

         11. Subjects who are of childbearing potential must have a negative screening serum
             pregnancy test.

        Exclusion Criteria

        Subjects who meet any of the following criteria will be excluded from this study:

          1. Have not recovered to ≤ Grade 1 toxicity from previous anticancer treatments or
             previous investigational products (IPs)

          2. Central nervous system metastasis, including leptomeningeal involvement

          3. Are currently receiving other medications intended for the treatment of their
             malignancy

          4. Received radiation therapy within 2 weeks prior to signing informed consent and those
             for whom radiation therapy is planned within 6 months from the time of signing
             informed consent

          5. Women who are pregnant or breastfeeding

          6. Uncontrolled intercurrent illness

          7. Known allergic reaction or intolerance to contrast media

          8. Documented history of true systemic allergic reaction to 3 or more medications

          9. For whom the Investigator believes that participation in this study would not be
             acceptable
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. D. Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kinex Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Goldfinch, MBA</last_name>
    <phone>716-427-2837</phone>
    <email>jgoldfinch@kinexpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>COIBA</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirta Varela</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMEDIC</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar D Duarte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Investigar</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Lerzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pastor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Rosario</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Tatangelo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan J Zarba</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CAIPO</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe S Palazzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación Arturo López Pérez</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Barajas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Referencia de Salud Cordillera Unidad de Patología Mamaria</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alonso U Obrador</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Borja Arriarán</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesar D Castillo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRAM</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro P Galaz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Alemana Temuco</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Rey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología E.S.E.</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo B Maya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Metropolitano de Santiago (HOMS)</name>
      <address>
        <city>Santiago</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael G Pilarte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa H Veras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital SOLCA</name>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mayra P Maridueña</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Andrade Martín</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelo D Molina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital SOLCA</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jenny C Guamán</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Cancer Center</name>
      <address>
        <city>Guatemala city</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Schaeffer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Privada</name>
      <address>
        <city>Guatemala city</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen S Sarmiento</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Privada</name>
      <address>
        <city>Guatemala city</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario F Castañeda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRESEM</name>
      <address>
        <city>Quetzaltenango</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio R Velasquez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Excel Medica</name>
      <address>
        <city>Cortés</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyapa A Cáceres</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tecnología en Investigación</name>
      <address>
        <city>Cortés</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge H Sabillón</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Oncológica Miraflores</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge F Sanchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Cayetano Heredia</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miro M Inocente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional del Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julio G Doroteo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Dominican Republic</country>
    <country>Ecuador</country>
    <country>Guatemala</country>
    <country>Honduras</country>
    <country>Peru</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 14, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
